The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics

Author： Cresci Sharon  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.15, 2005-12, pp. : 2577-2591

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenetics of the PPAR genes and cardiovascular disease

By Cresci Sharon  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1581-1595

Future Medicine

Access to resources Recommend Favorite

PPAR-&ggr; Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-06 ,pp. : 292-300

Bentham Science Publishers

Access to resources Recommend Favorite

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk

By  

Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. : 894-902

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist: Implications for Cardiovascular Disease in Patients with Diabetes Mellitus

By Cavender Matthew A.   Lincoff A. Michael  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 209-216

Adis International

Access to resources Recommend Favorite

PPAR-γ: Therapeutic Prospects in Parkinson's Disease

By  

Current Drug Targets, Vol. 14, Iss. 7, 2013-06 ,pp. : 743-751

Bentham Science Publishers

Access to resources Recommend Favorite